RhumbLine Advisers
NMTR

RhumbLine Advisers’s 9 Meters Biopharma NMTR Stock Holding History

RhumbLine Advisers’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,733
Closed -$93K – 3301
2022
Q1 		$93K Buy
7,733
+172
+2% +$2.35K ﹤0.01% 2899
2021
Q4 		$148K Sell
7,561
-163
-2% -$3.65K ﹤0.01% 2887
2021
Q3 		$201K Buy
7,724
+500
+7% +$11.8K ﹤0.01% 2915
2021
Q2 		$159K Buy
+7,224
New +$177K ﹤0.01% 2940
2019
Q2 		– Sell
-1,149
Closed -$44K – 3022
2019
Q1 		$44K Sell
1,149
-20
-2% -$865 ﹤0.01% 2925
2018
Q4 		$54K Buy
1,169
+375
+47% +$27.8K ﹤0.01% 2938
2018
Q3 		$108K Sell
794
-49
-6% -$8.42K ﹤0.01% 2856
2018
Q2 		$398K Buy
+843
New +$310K ﹤0.01% 2406

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Curi Wealth Management Raleigh, North Carolina $724M AUM 17.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

RhumbLine Advisers's NMTR Position: Q2 2022 in Review

RhumbLine Advisers sold out of 9 Meters Biopharma (NMTR) in Q2 2022, closing a stake of 7,733 shares — an estimated $93K sold.

RhumbLine Advisers first reported a position in NMTR in Q2 2018 and held it in 8 quarters. The position peaked at $398K in Q2 2018. 88 funds tracked by Wall St. Rank hold NMTR as of Q2 2022.

  • RhumbLine Advisers reported no remaining 9 Meters Biopharma position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 7,733 9 Meters Biopharma shares in Q2 2022, an estimated $93K.
  • RhumbLine Advisers first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 8 quarters.
  • RhumbLine Advisers's 9 Meters Biopharma position peaked at $398K in Q2 2018.
  • 88 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.